Skip to main content
SpringerLink
Log in

Chemotherapy for Advanced Non-small Cell Lung Cancer

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 170))

Abstract

Non-small cell lung cancer has seen an unprecedented augmentation of therapeutic options over the last couple of years. Improved understanding of molecular drivers and the role of the immune system in cancer therapy have brought new drugs to the armamentarium. Despite these advances, cytotoxic chemotherapy remains a substantial part of therapy for most patients in locally advanced and metastatic stage. Initially thought to be a chemotherapy-resistant entity, meta-analyses in the mid-1990s demonstrated modest efficacy of platinum-based therapy. Further combination trials demonstrated enhanced efficacy for several regimen in first and second lines, including the introduction of antimetabolites, taxanes, and anti-angiogenic agents. Maintenance chemotherapy has been another novel, successful approach for management of metastatic disease. Herein, we summarize the current concepts of chemotherapy, its applicability to the different histologies, and novel concepts of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goodgame B, Viswanathan A, Zoole J et al (2009) Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 4:1370–4

    Article  PubMed  Google Scholar 

  2. BMJ (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909

    Google Scholar 

  3. Jemal A, Thun MJ, Ries LA et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672–94

    Article  PubMed  PubMed Central  Google Scholar 

  4. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317:771–5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wassenaar TR, Eickhoff JC, Jarzemsky DR, Smith SS, Larson ML, Schiller JH (2007) Differences in primary care clinicians’ approach to non-small cell lung cancer patients compared with breast cancer. J Thorac Oncol 2:722–8

    Article  PubMed  Google Scholar 

  6. Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE (2010) Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 5:1529–35

    Article  PubMed  PubMed Central  Google Scholar 

  7. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC (2002) Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 20:1786–92

    Article  PubMed  Google Scholar 

  8. Earle CC, Venditti LN, Neumann PJ et al (2000) Who gets chemotherapy for metastatic lung cancer? Chest 117:1239–46

    Article  CAS  PubMed  Google Scholar 

  9. Ramsey SD, Howlader N, Etzioni RD, Donato B (2004) Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 22:4971–8

    Article  PubMed  Google Scholar 

  10. Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–62

    Article  CAS  PubMed  Google Scholar 

  11. Paz-Ares L, de Marinis F, Dediu M et al (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247–55

    Article  CAS  PubMed  Google Scholar 

  12. Navari RM, Reinhardt RR, Gralla RJ et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 340:190–5

    Article  CAS  PubMed  Google Scholar 

  13. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH (1994) Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 12:1245–50

    CAS  PubMed  Google Scholar 

  14. Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–42

    Article  CAS  PubMed  Google Scholar 

  15. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–50

    Article  CAS  PubMed  Google Scholar 

  16. Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–73

    Article  CAS  PubMed  Google Scholar 

  17. de Marinis F, De Santis S, De Petris L (2006) Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies. Semin Oncol 33:S17–24

    Article  PubMed  CAS  Google Scholar 

  18. Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus PE (2003) ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14:455–60

    Article  CAS  PubMed  Google Scholar 

  19. Smit EF, Socinski MA, Mullaney BP et al (2012) Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol 23:1723–9

    Article  CAS  PubMed  Google Scholar 

  20. Bridges JF, Mohamed AF, Finnern HW, Woehl A, Hauber AB (2012) Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer 77:224–31

    Article  PubMed  Google Scholar 

  21. Peeters L, Sibille A, Anrys B et al (2012) Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients’ perceptions. J Thorac Oncol 7:1291–5

    Article  PubMed  Google Scholar 

  22. Katayama R, Shaw AT, Khan TM et al (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Science Trans Med 4:120ra17

    Google Scholar 

  23. Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–92

    Article  CAS  PubMed  Google Scholar 

  24. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618–26

    CAS  PubMed  Google Scholar 

  25. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 106:861–5

    Article  CAS  PubMed  Google Scholar 

  26. Los G, Verdegaal E, Noteborn HP et al (1991) Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol 42:357–63

    Article  CAS  PubMed  Google Scholar 

  27. Peng B, Tilby MJ, English MW et al (1997) Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer 76:1466–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ardizzoni A, Boni L, Tiseo M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–57

    Article  CAS  PubMed  Google Scholar 

  29. Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348–58

    Article  PubMed  Google Scholar 

  30. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–8

    Article  CAS  PubMed  Google Scholar 

  31. Gerber DE, Grossman SA, Batchelor T, Ye X (2007) Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 59:817–23

    Article  CAS  PubMed  Google Scholar 

  32. Ranson M, Davidson N, Nicolson M et al (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074–80

    Article  CAS  PubMed  Google Scholar 

  33. Roszkowski K, Pluzanska A, Krzakowski M et al (2000) A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145–57

    Article  CAS  PubMed  Google Scholar 

  34. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern cooperative oncology group results. J Natl Cancer Inst 85:388–94

    Article  CAS  PubMed  Google Scholar 

  35. Murphy WK, Fossella FV, Winn RJ et al (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384–8

    Article  CAS  PubMed  Google Scholar 

  36. Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern cooperative oncology group trial. J Clin Oncol 18:623–31

    CAS  PubMed  Google Scholar 

  37. Giaccone G, Splinter TA, Debruyne C et al (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European organization for research and treatment of cancer lung cancer cooperative group. J Clin Oncol 16:2133–41

    CAS  PubMed  Google Scholar 

  38. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest oncology group trial. J Clin Oncol 19:3210–8

    CAS  PubMed  Google Scholar 

  39. Miller VA, Rigas JR, Francis PA et al (1995) Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968–72

    Article  CAS  PubMed  Google Scholar 

  40. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T (1996) Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14:1649–55

    CAS  PubMed  Google Scholar 

  41. Burris HA 3rd, Fields S, Peacock N (1995) Docetaxel (Taxotere) in combination: a step forward. Semin Oncol 22:35–40

    CAS  PubMed  Google Scholar 

  42. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–30

    CAS  PubMed  Google Scholar 

  43. Cardenal F, Lopez-Cabrerizo MP, Anton A et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12–8

    CAS  PubMed  Google Scholar 

  44. Saha A, Rudd R (2006) Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer? Expert Rev Anticancer Ther 6:165–73

    Article  CAS  PubMed  Google Scholar 

  45. Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E (2002) Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 37:9–14

    Article  PubMed  Google Scholar 

  46. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–44

    Article  CAS  PubMed  Google Scholar 

  47. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–51

    Article  CAS  PubMed  Google Scholar 

  48. Shimizu T, Nakagawa Y, Takahashi N, Hashimoto S (2015) Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer. Clin Transl Oncol 18(1):107–112

    Google Scholar 

  49. Kutluk Cenik B, Sun H, Gerber DE (2013) Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer 80:326–332

    Google Scholar 

  50. Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23:68–72

    Article  CAS  PubMed  Google Scholar 

  51. Dickgreber NJ, Sorensen JB, Paz-Ares LG et al (2010) Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 16:2872–80

    Article  CAS  PubMed  Google Scholar 

  52. Gridelli C, Perrone F, Gallo C et al (1997) Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 33:392–7

    Article  CAS  PubMed  Google Scholar 

  53. Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest oncology group study. J Clin Oncol 16:2459–2465

    CAS  PubMed  Google Scholar 

  54. van Meerbeeck JP, Legrand C, van Klaveren RJ, Giaccone G (2001) Group ELC. Chemotherapy for non-small-cell lung cancer. Lancet 358:1271–1272

    Google Scholar 

  55. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285–4291

    Article  CAS  PubMed  Google Scholar 

  56. Comella P, Panza N, Manzione L, et al (2000) Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine versus either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small-cell lung cancer. A Southern italy cooperative oncology group study. Clin Lung Cancer 1:202–207; discussion 8

    Google Scholar 

  57. Comella P (2001) Southern Italy cooperative oncology G. phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28:7–10

    Article  CAS  PubMed  Google Scholar 

  58. Kodani T, Ueoka H, Kiura K et al (2002) A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 36:313–319

    Article  PubMed  Google Scholar 

  59. Souquet PJ, Tan EH, Rodrigues Pereira J et al (2002) GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 13:1853–61

    Article  CAS  PubMed  Google Scholar 

  60. Goffin JR, Anderson IC, Supko JG et al (2005) Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11:3417–24

    Article  CAS  PubMed  Google Scholar 

  61. Morra F, Luise C, Visconti R et al (2015) New therapeutic perspectives in CCDC6 deficient lung cancer cells. Int J Cancer 136:2146–57

    Article  CAS  PubMed  Google Scholar 

  62. Tarhini AA, Zahoor H, McLaughlin B et al (2013) Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. Anticancer Res 33:4475–81

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Langer CJ, Novello S, Park K et al (2014) Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 32:2059–66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Socinski MA, Goldman J, El-Hariry I et al (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068–77

    Article  CAS  PubMed  Google Scholar 

  65. Fidler IJ, Ellis LM (2004) Neoplastic angiogenesis—not all blood vessels are created equal. N Engl J Med 351:215–6

    Article  CAS  PubMed  Google Scholar 

  66. Forsythe JA, Jiang BH, Iyer NV et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Jiang BH, Agani F, Passaniti A, Semenza GL (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328–5335

    CAS  PubMed  Google Scholar 

  68. Xu Q, Briggs J, Park S et al (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552–5560

    Article  CAS  PubMed  Google Scholar 

  69. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191

    Article  CAS  PubMed  Google Scholar 

  70. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227–1234

    Article  CAS  PubMed  Google Scholar 

  71. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern cooperative oncology group study. Clin Cancer Res 14:1407–1412

    Article  CAS  PubMed  Google Scholar 

  72. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949–954

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Iwamoto S, Takahashi T, Tamagawa H et al (2015) FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 26:1427–1433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155

    Article  CAS  PubMed  Google Scholar 

  75. Pirker R (2012) EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Transl Lung Cancer Res 1:269–75

    PubMed  PubMed Central  Google Scholar 

  76. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531

    Article  CAS  PubMed  Google Scholar 

  77. Socinski MA, Schell MJ, Peterman A et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335–1343

    Article  CAS  PubMed  Google Scholar 

  78. Soon YY, Stockler MR, Askie LM, Boyer MJ (2009) Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 27:3277–83

    Article  PubMed  Google Scholar 

  79. Gerber DE, Schiller JH (2013) Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 31:1009–1020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Lopez-Chavez A, Young T, Fages S et al (2012) Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern cooperative oncology group 4599 Study: results of an exploratory analysis. J Thorac Oncol 7:1707–1712

    Article  CAS  PubMed  Google Scholar 

  81. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–83

    Article  CAS  PubMed  Google Scholar 

  82. Gridelli C, de Marinis F, Pujol JL et al (2012) Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 7:1713–21

    Article  CAS  PubMed  Google Scholar 

  83. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432–1440

    Article  CAS  PubMed  Google Scholar 

  84. Brugger W, Triller N, Blasinska-Morawiec M et al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113–20

    Article  CAS  PubMed  Google Scholar 

  85. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521–529

    Article  CAS  PubMed  Google Scholar 

  86. Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591–598

    Article  CAS  PubMed  Google Scholar 

  87. Brodowicz T, Krzakowski M, Zwitter M et al (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52:155–163

    Article  PubMed  Google Scholar 

  88. Belani CP, Dakhil S, Waterhouse DM et al (2007) Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 18:110–115

    Article  CAS  PubMed  Google Scholar 

  89. Barlesi F, Scherpereel A, Rittmeyer A et al (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004–3011

    Article  CAS  PubMed  Google Scholar 

  90. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    Article  CAS  PubMed  Google Scholar 

  91. Alexopoulos K, Kouroussis C, Androulakis N et al (1999) Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol 43:257–262

    Article  CAS  PubMed  Google Scholar 

  92. Gandara DR, Vokes E, Green M et al (2000) Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 18:131–135

    CAS  PubMed  Google Scholar 

  93. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

    CAS  PubMed  Google Scholar 

  94. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  95. Gregorc V, Novello S, Lazzari C et al (2014) Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 15:713–721

    Article  CAS  PubMed  Google Scholar 

  96. Camps C, Massuti B, Jimenez A et al (2006) Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17:467–472

    Article  CAS  PubMed  Google Scholar 

  97. Al-Minawi AZ, Lee YF, Hakansson D et al (2009) The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 37:6400–6413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991

    Article  CAS  PubMed  Google Scholar 

  99. Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368:1101–1110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Gong W, Zhang X, Wu J et al (2012) RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 75:374–380

    Article  PubMed  Google Scholar 

  101. Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808–5815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Sun JM, Ahn JS, Jung SH et al (2015) Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized phase II trial. J Clin Oncol 33:2450–2456

    Article  CAS  PubMed  Google Scholar 

  103. Tang H, Xiao G, Behrens C et al (2013) A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res 19:1577–1586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Kim HS, Mendiratta S, Kim J et al (2013) Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155:552–566

    Article  CAS  PubMed  Google Scholar 

  105. Byers LA, Diao L, Wang J et al (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3 K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19:279–290

    Article  CAS  PubMed  Google Scholar 

  106. Langer CJ, Manola J, Bernardo P et al (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 94:173–181

    Article  PubMed  Google Scholar 

  107. Wakelee HA, Dahlberg SE, Brahmer JR et al (2012) Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern cooperative oncology group (ECOG) studies, with and without bevacizumab. Lung Cancer 76:410–415

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Lilenbaum RC, Herndon JE 2nd, List MA et al (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23:190–196

    Article  CAS  PubMed  Google Scholar 

  109. Abe T, Takeda K, Ohe Y et al (2015) Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol 33:575–581

    Article  CAS  PubMed  Google Scholar 

  110. Quoix E, Zalcman G, Oster JP et al (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 378:1079–1088

    Article  CAS  PubMed  Google Scholar 

  111. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D (2008) Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3:125–129

    Article  PubMed  Google Scholar 

  112. Lilenbaum R, Rubin M, Samuel J et al (2007) A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2:306–311

    Article  PubMed  Google Scholar 

  113. Lilenbaum R, Villaflor VM, Langer C et al (2009) Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 4:869–874

    Article  PubMed  Google Scholar 

  114. Stinchcombe TE, Buzkova P, Choksi J et al (2006) A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 52:305–311

    Article  PubMed  Google Scholar 

  115. Zukin M, Barrios CH, Pereira JR et al (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31:2849–2853

    Article  CAS  PubMed  Google Scholar 

  116. Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400

    Article  CAS  PubMed  Google Scholar 

  117. Lilenbaum R, Axelrod R, Thomas S et al (2008) Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 26:863–869

    Article  CAS  PubMed  Google Scholar 

  118. Goss G, Ferry D, Wierzbicki R et al (2009) Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 27:2253–2260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harold C. Simmons Cancer Center, Division of Hematology-Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, 8852, Dallas, TX, 75390-8852, USA

    Martin F. Dietrich & David E. Gerber

Authors
  1. Martin F. Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David E. Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Martin F. Dietrich or David E. Gerber .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, City of Hope, Duarte, California, USA

    Karen L. Reckamp

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dietrich, M.F., Gerber, D.E. (2016). Chemotherapy for Advanced Non-small Cell Lung Cancer. In: Reckamp, K. (eds) Lung Cancer. Cancer Treatment and Research, vol 170. Springer, Cham. https://doi.org/10.1007/978-3-319-40389-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40389-2_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40387-8

  • Online ISBN: 978-3-319-40389-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation